Morton Brown Family Wealth’s Recursion Pharmaceuticals RXRX Stock Holding History

Morton Brown Family Wealth’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.47K	Hold	400	–	–	﹤0.01%	280
2026 Q1	$1.23K	Hold	400	–	–	﹤0.01%	263
2025 Q4	$1.64K	Hold	400	–	–	﹤0.01%	262
2025 Q3	$1.95K	Hold	400	–	–	﹤0.01%	243
2025 Q2	$2.02K	Hold	400	–	–	﹤0.01%	281
2025 Q1	$2.12K	Hold	400	–	–	﹤0.01%	279
2024 Q4	$2.7K	Hold	400	–	–	﹤0.01%	221
2024 Q3	$2.64K	Hold	400	–	–	﹤0.01%	219
2024 Q2	$3.15K	Buy	+400	New	+$3.49K	﹤0.01%	183

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morton Brown Family Wealth's RXRX Position: Q2 2026 in Review

Morton Brown Family Wealth held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 400 shares worth $1.47K. The position accounts for ﹤0.01% of the portfolio, ranked #280.

Morton Brown Family Wealth first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $3.15K in Q2 2024. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Morton Brown Family Wealth held 400 shares of Recursion Pharmaceuticals worth $1.47K as of Q2 2026.
Morton Brown Family Wealth left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Morton Brown Family Wealth's portfolio in Q2 2026, its #280 holding.
Morton Brown Family Wealth first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Morton Brown Family Wealth's Recursion Pharmaceuticals position peaked at $3.15K in Q2 2024.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Morton Brown Family Wealth's 13F filing for Q2 2026, filed 21 Jul 2026.